|
| |
Agilent Technologies and BioTrove Sign Collaborative
Marketing Agreement for Ultra-High-Throughput Mass Spectrometry Solution
Collaboration to Improve Drug-Discovery Efficiency through Automated Sample
Preparation, Analysis with Unsurpassed Throughput
SANTA CLARA, Calif., and WOBURN, Mass., Oct. 17, 2007 -- Agilent Technologies
Inc. (NYSE: A) and BioTrove Inc. today announced they have signed an agreement
to co-market the Agilent 6410 Triple Quadrupole Mass Spectrometer with
BioTrove’s RapidFire high-throughput sample preparation systems. The two systems
together provide an integrated solution for ultra-high-throughput preparation
and analysis of in vitro biological assays in pharmaceutical drug research.
“This relationship enables clients to integrate the fastest sample-preparation
system on the market with the strength of leading-edge analytical mass
spectrometry,” said Guenter Nill, Agilent general manager, pharmaceutical and
biotech market. “It significantly benefits pharmaceutical companies that want to
spend less time and money discovering new leads and developing more effective
medicines.”
Using innovative microfluidic technology for sample preparation and analysis
faster than eight seconds per sample, RapidFire Mass Spectrometry (RF-MS)
eliminates bottlenecks created by traditional mass spectrometry throughput. It
has been used by 10 of the top 15 pharmaceutical companies as an established
drug-discovery tool for more than four years. RF-MS is routinely used in
applications including the high-throughput screening of previously intractable
drug targets, cytochrome P450 inhibition as well as in directed evolution
studies.
The Agilent 6410 Triple Quadrupole LC/MS establishes a new standard for value in
a triple quadrupole mass spectrometer, delivering outstanding sensitivity and
great ease of use along with traditional Agilent reliability. Femtogram-level
sensitivity and rugged, reliable performance make this the instrument of choice
for drug discovery and development.
“The Agilent-BioTrove collaboration provides an improved, integrated
high-throughput screening solution, enabling biopharmaceutical companies to
better use their talent, time and targets,” said Al Luderer, Ph.D., president
and CEO, BioTrove. “BioTrove’s expertise in sample preparation for
high-throughput screening and early ADME is a natural complement to Agilent’s
strength in analytical mass spectrometry. Together, we are enabling walk-away
analysis of lead compounds against valuable targets that would be otherwise
impossible to screen, helping biopharma clients meet the challenge of
accelerating drug discovery research.”
The combined solutions can be seen at the following events:
- Chemical and Pharmaceutical Structure Analysis
Conference in Langhorne, Pa., on Oct. 22-25; and
- American Association of Pharmaceutical Scientists
Conference in San Diego on Nov. 11-15.
About BioTrove
BioTrove Inc. offers two innovative technology platforms: RapidFire, which
enables the acceleration of drug discovery and pipeline decisions, and OpenArray,
which advances genomic research in a wide range of life science fields,
including agriculture, disease research, bio-defense and public health. With
more than half of the world’s ten largest pharmaceutical companies as clients,
and partnerships with prestigious research and public health centers around the
world, BioTrove’s products and services ensure that an industry committed to
accuracy and speed can meet business goals.
For more information, please visit
www.biotrove.com .
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement
company and a technology leader in communications, electronics, life sciences
and chemical analysis. The company’s 19,000 employees serve customers in more
than 110 countries. Agilent had net revenue of $5.0 billion in fiscal 2006.
Information about Agilent is available on the Web at
www.agilent.com .
# # #
Further technology, corporate citizenship and executive news is available on the
Agilent news site at
www.agilent.com/go/news .
Press release URL:
http://www.agilent.com/about/newsroom/presrel/2007/17oct-ca07058.html
Additional metadata keywords (for Web use only): ultra high throughput mass
spectrometry, BioTrove, triple quadrupole, in vitro biological assays,
pharmaceutical drug research
--END--
PRCA07058
EDITORIAL CONTACTS:
Claudia Hachtel, Agilent Technologies
Nicki Muir, Alto Marketing
+49-7243-602 100
+44-1489-55 76 72
claudia_hachtel@agilent.com
nickim@alto-marketing.com
Sarah Perceval, Alto Marketing
+44-1489-55 76 72
sarahp@alto-marketing.com
| |
|
